Document: Joint HTAb-regulatory perspectives on understanding evidence challenges, managing uncertainties and exploring potential solutions-2025/4/2

Page: Biosimilar medicines: Overview-2025/4/2

Page: Tolvaptan product-specific bioequivalence guidance-2025/4/2

Document: Rules of procedure for the Patients and Consumers Working Party (PCWP) and the Healthcare Professionals Working Party (HCPWP)-2025/4/2

Document: Mandate, objectives and composition of the Patients and Consumers Working Party (PCWP)-2025/4/2

Document: Mandate, objectives and composition of the Healthcare Professionals Working Party (HCPWP)-2025/4/2

Page: Data in regulation: Big data and other sources-2025/4/1

Page: Plasma master file certificates-2025/4/1

Document: Clinical Trial Information System (CTIS) structured data form - Initial application, additional Member State Concerned, substantial modification, non-substantial modification-2025/4/1

Document: Day 80 assessment report - Non-clinical template with guidance Rev. 03.25 - Revamp-2025/4/1